
A new era for Blue Guardian as the prop firm has revealed its exclusive acquisition of an ASIC-regulated broker. This unique partnership will set Blue Guardian apart in the prop trading space, reducing the risk of potential shutdowns that have impacted other brokers.
Moreover, the transition to the new broker is well underway, with Blue Guardian aiming to complete the process by Wednesday of next week. This strategic move is going to provide a dedicated and optimized trading space specifically tailored for Blue Guardian’s non-US clients, offering highly favorable trading conditions. As part of this transition, the firm plans to rebrand the broker, aligning it more closely with the overarching theme of Blue Guardian.
Blue Guardian Exclusive Acquisition of ASIC-Regulated Broker
Also, for valued customers in the United States, Blue Guardian has plans in place to ensure a seamless transition. Blue Guardian assures its US clients that arrangements are being finalized to enable them to start using DXtrade by this Friday.
In an additional announcement, Blue Guardian expressed its excitement about the upcoming availability of MatchTrader, a new platform to enhance the firm’s services even further. Anticipated to be accessible in just two weeks, MatchTrader promises to bring additional features and capabilities to Blue Guardian.
Also, Blue Guardian remains committed to providing top-notch services to its traders, both in the US and internationally. Lastly, the recent moves aim to fortify the firm’s position in the market. They also ensure a more tailored and secure trading environment for its clientele.
About the Firm
Here are some interesting facts about the firm:
- Excellent Trustpilot Rating of 4.7/5
- Three Unique Funding Programs
- Professional Trader Dashboard
- A Large Variety of Trading Instruments (Forex Pairs, Commodities, Indices, Cryptocurrencies)
- Leverage up to 1:100
- No Minimum & Maximum Trading Day Requirements
- Scaling Plan
Also, use our Discount Code (forexpropreviews) for a 10% Discount or read the Review.